Immunovia Publishes Interim Report for January-September 2023
July-September 2023 · Net sales amounted to KSEK 488 (358) divided by sales of tests KSEK 70 (111) and royalties KSEK 418 (247). · Net earnings were MSEK -38.6 (-22.9) and earnings per share before and after dilution were SEK -0.91 (1.01). · Cash Flow from operating activities amount to MSEK -35 (-37). · Cash and equivalents at the end of the period amounted to MSEK 107 (159). · On July 11, the Company announced that it will cease commercialization of IMMray™ PanCan-d test in the United States to focus its resources on development of the next-generation pancreatic cancer